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Abstract
Composite biomaterials comprising nanostructured hydroxyapatite (HAp) have an enormous 
potential for natural bone tissue reparation, filling and augmentation. Chitosan (Ch) as a naturally 
derived polymer has many physicochemical and biological properties that make it an attractive 
material for use in bone tissue engineering. On the other hand, poly-D,L-lactide-co-glycolide 
(PLGA) is a synthetic polymer with a long history of use in sustained drug delivery and tissue 
engineering. However, while chitosan can disrupt the cell membrane integrity and may induce 
blood thrombosis, PLGA releases acidic byproducts that may cause tissue inflammation and 
interfere with the healing process. One of the strategies to improve the biocompatibility of Ch and 
PLGA is to combine them with compounds that exhibit complementary properties. In this study 
we present the synthesis and characterization, as well as in vitro and in vivo analyses of a 
nanoparticulate form of HAp coated with two different polymeric systems: (a) Ch and (b) a Ch-
PLGA polymer blend. Solvent/non-solvent precipitation and freeze-drying were used for synthesis 
and processing, respectively, whereas thermogravimetry coupled with mass spectrometry was 
used for phase identification purposes in the coating process. HAp/Ch composite particles 
exhibited the highest antimicrobial activity against all four microbial strains tested in this work, 
but after the reconstruction of the bone defect they also caused inflammatory reactions in the 
newly formed tissue where the defect had lain. Coating HAp with a polymeric blend composed of 
Ch and PLGA led to a decrease in the reactivity and antimicrobial activity of the composite 
particles, but also to an increase in the quality of the newly formed bone tissue in the reconstructed 
defect area.
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1. Introduction
Synthetic nanostructured hydroxyapatite (HAp) over and over again proves to be a material 
of interest not only for bone tissue engineering, but also for multiple other areas of research, 
ranging from adsorbents to sensors to optical imaging to controlled drug delivery [1–5]. 
Enhancement of the properties of HAp proceeds along two main routes: (i) manipulation of 
microstructure; (ii) combination with other elements and materials. The room for such 
improvements is apparently limitless. As for the control of microstructure, it is known that 
parameters such as morphology [6], crystallinity [7], grain [8] and particle size [9,10], 
topography [11], porosity [12] or compositional gradient [13] have an immense effect on the 
physical properties and bioactivity of HAp. As for doping HAp, each of its three constitutive 
ions — calcium, phosphate and hydroxyl — can be substituted with other ions and dozens of 
chemically different forms of HAp are known so far [14]. Hydrothermal synthesis has been 
used in our lab to create nanostructured HAp in which calcium ions were substituted with 
cobalt, and the resulting material exhibited good biological properties during in vivo testing 
[15]. Other ionic substitutions, including predominantly Mg, Zn, Si, Sr, Fe, Co and 
carbonate, alongside rarer dopants, e.g., K, Na, Se, lanthanides and radionuclides, were 
noted in the literature [16].
Advancement of nanotechnologies allows for the design of a large number of hybrid, 
multicomponent systems based on HAp as the central ingredient [17]. Coating HAp particles 
with bioresorbable synthetic polymers based on poly(lactic-co-glycolic acid) (PLGA) has 
thus produced materials suitable for filling bone defects [18,19]. Biocompatible polymeric 
coatings around HAp particles made possible the development of multifunctional 
nanoparticle systems with immobilized active pharmaceutics, including vitamins and 
antibiotics [20,21]. Such combinations of soft, polymeric and hard, mineral components are 
also thought to be the route to creating materials that would mimic the natural properties of 
bone [22].
Chitosan is a bioderived polysaccharide obtained mainly from shells of crustaceans, corals 
or jellyfish. Because of its biocompatibility and a range of interesting properties, including 
antimicrobial, antitumor, anti-inflammatory and immunity-enhancing ones [23–26], chitosan 
could serve a multifunctional purpose in biomedicine [27]. However, the cationic nature of 
chitosan can compromise the cell membrane integrity and promote cytotoxicity [28–31]. It 
can also induce thrombosis [32], and this is what makes the material improper for wider use. 
There are different strategies for increasing hemocompatibility of chitosan and they are 
chiefly directed at its chemical modification or mixing with other compounds which exhibit 
complementary features [33]. HAp particles combined with chitosan, a bioderived polymer, 
have produced a large interest in bone tissue engineering community because of a generally 
positive biological response thereto [34,35]. This type of composite material following in 
vivo implantation induced osteon formation, indicating successful vascularization of the 
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reconstructed defect [36]. Injectable systems based on HAp and chitosan, incorporating bone 
marrow mesenchymal stem cells, also promoted ectopic bone formation in vivo [37]. A 
three-dimensional (3-D) HAp and chitosan scaffold also proved to be a good substrate for 
stem cells in regenerative medicine of bone tissue [38]. Also, macroporous 3-D HAp-
chitosan scaffolds in form of interconnected networks of polymeric matrices were used to 
repair damaged or diseased bones [39].
While chitosan can disrupt the cell membrane integrity and is also unsuitable as a blood–
contacting biomaterial, the most frequently used synthetic polymer in bone tissue 
engineering, PLGA, releases acidic byproducts that may cause tissue inflammation and 
interfere with the healing process [40,41]. One of the strategies to improve the 
biocompatibility of chitosan and PLGA per se may thus be to combine them with 
compounds that exhibit complementary properties, including one another. The subject of 
this study is correspondingly nanoparticles of HAp, uncoated and coated with chitosan and 
chitosan-PLGA polymer blend. Thermogravimetry coupled with mass spectrometry was 
used for phase identification purposes in the coating process. The obtained powders 
composed of spherical particles with controlled size distribution were then used as fillers in 
the reconstruction of artificially formed bone defects in vivo. This was preceded by the 
analysis of their interaction with osteoblastic cells in vitro as well as of antibacterial 
properties against four microbial strains: S. aureus, S. epidermis, P. aeruginosa, E. coli. The 
antimicrobial potency of the synthesized materials was correlated with the osteoregenerative 
properties evaluated in vivo.
2. Materials and methods
2.1. Synthesis of materials
Aqueous calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6 wt%) was added to the basic 
solution of ammonium phosphate ((NH4)3PO4) (7 ml H3PO4 + 165 ml NH4OH + 228 ml 
H2O) at 50 °C and stirred at 100 rpm over the period of 60 min. The solution was then 
subjected to a heat treatment for 60 min at 100 °C. The obtained gel was then subjected to 
freeze drying at −10 to −60 °C and under pressures ranging from 0.37 mbar to 0.1 mbar over 
a period between one and four hours (Christ Alpha 1–2/LD Plus). The obtained product was 
pure hydroxyapatite powder (HAp) [18].
Chitosan (Ch) of a low molecular weight (Aldrich, deacetylation >75%) dissolved in acetic 
acid (1 wt%) was mixed with HAp gel in the 4:6 mass ratio while stirring with a magnetic 
stirrer at 400 rpm. Distilled water was added dropwise to the mixture of chitosan and HAp 
gel, while stirring at 21,000 rpm (Ultra-Turrax T25, IKA, Germany). The obtained mixture 
of chitosan and HAp was slowly poured into a glutaraldehyde solution (Grade I, 25% in 
H2O) and stirred at the rate of 21,000 rpm for one hour. The resulting mixture was then 
centrifuged at 5000 rpm and 5 °C for one hour (Hettich Universal 320R). After that, the 
mixture was decanted, washed twice with distilled water and dried at 20 °C and 1 bar for 12 
h in a dry oven (Selecta Vaciotem). The obtained powder was then subjected to freeze 
drying at −10 to −60 °C, and at pressures ranging from 0.37 mbar to 0.1 mbar for one to six 
hours. The obtained product was a powder composed of chitosan-coated HAp particles 
(HAp/Ch) [42].
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PLGA (50:50, Sigma, USA) and chitosan, dissolved in acetone and acetic acid, respectively, 
were mixed with the HAp gel in the mass ratio of 2:2:6. The water solution of poloxamer 
188 (polyethylenepolypropylene glycol, 0.1 vol.%) was added dropwise to the mixture of 
chitosan, PLGA and HAp, while stirring at 21,000 rpm. The obtained mixture of chitosan, 
PLGA and the HAp was slowly poured into a glutaraldehyde solution (Grade I, 25% in 
H2O) and stirred at the rate of 21,000 rpm for one hour. The obtained mixture was then 
centrifuged at 500 rpm and 5 °C for one hour. After that, the mixture was decanted, washed 
twice with distilled water and dried at 20 °C and 1 bar for 12 h in a dry oven (Selecta 
Vaciotem). The obtained powder was then subjected to freeze drying at −10 to −60 °C, and 
at pressures ranging from 0.37 mbar to 0.1 mbar for one to eight hours. The obtained 
product was the powder composed of HAp particles coated with chitosan/poly(D,L)-lactide-
co-glycolide (HAp/Ch-PLGA) [42].
2.2. Characterization of the materials
X-ray diffraction (XRD) was performed on a Philips PW-1050 diffractometer with Ni-
filtered CuKα radiation. Field-emission scanning electron microscopy (FE-SEM) 
measurements were performed on a MIRA 3 MXU (High resolution SEM, Tescan) 
microscope. Infrared spectroscopy (FTIR) was done using the KBr technique on a BOMEM 
MB-100 spectrometer (Hartmann & Braun, Canada) and in the spectral range from 400 to 
4000 cm−1. The spectral resolution was 2 cm−1. A simultaneous thermal analysis was 
performed using Thermo-Gravimetric Analysis/Differential-Thermal Analysis (TGA/DTA), 
SETSYS 2400 CS Evolution (Setaram Instrumentation) coupled with a gas analysis mass 
spectrometric system (MS) (Omni Star GSD 320, Pfeiffer). Samples of 10 ± 0.5 mg were 
analyzed in air atmosphere flow by heating (10 °C/min) them from 28 to 600 °C. The 
particle size distribution (PSD) was measured on 10 mg/ml of the powder dispersed in water 
using a Mastersizer 2000 (Malvern Instruments Ltd.) and a HydroS dispersion unit for liquid 
dispersants.
2.3. Antimicrobial activity test (micro-well dilution assay)
in vitro antibacterial activity of HAp, HAp/Ch and HAp/Ch-PLGA was evaluated in 
reference to laboratory strains of Escherichia coli (ATCC 8739), Pseudomonas aeruginosa 
(ATCC 9027), Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 
12228), and Candida albicans (ATCC 10231), using Micro-well Dilution Assay [43]. Prior 
to the test, the powdered samples were sterilized by means of a UV lamp so as to avoid 
microorganism impurities. The inocula of the microbial strains were prepared from the 
overnight broth cultures and suspensions were made in sterile saline (0.9% NaCl). Their 
optical density was standardized to 0.5 M McFarland solution, corresponding to 107–108 
CFU/mL. Stock solutions of samples were prepared in the sterile potassium hydrogen 
phosphate buffer. Serial double dilutions were tested in the range of 31.2–0.015 mg/mL, 
9.2–0.004 mg/mL and 12.8–0.006 mg/mL in a 96-well microtiter plate with inoculated 
Mueller-Hinton broth (pH 7.3) for bacteria and Sabouraud dextrose broth (pH 5.6) for yeast 
(Institute for Immunology and Virology, Torlak, Belgrade). The final volume was 100 μL 
and the final concentration was 106 CFU/mL in each well. The plate was incubated for 24 h 
at 37 °C. All experiments were performed in triplicates, where two growth controls were 
included: the corresponding medium with the potassium hydrogen phosphate buffer as a 
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negative control, and antibiotics tetracycline and nystatin (Appl. Chem) as the positive 
control. The bacterial growth was determined by adding 20 μL of 0.5% TTC (triphenyl 
tetrazolium chloride) aqueous solution to the plate. Analysis of variance (ANOVA) was 
used to determine the statistical significance (p ≤ 0.05) of the obtained data.
2.4. In vitro experimental design
2.4.1. Cell culture—Mouse calvarial MC3T3-E1 cells were obtained from ATCC and 
cultured in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum, 5% 
antibiotic/antimycotic and 100μg/ml of ascorbic acid to induce differentiation from 
fibroblastic to osteoblastic lineage.
2.4.2. Immunohistochemistry—MC3T3-E1 cells were plated onto glass coverslips at a 
density of 5 × 105 cells/well in 24 well plates along with 3 mg of nanopowders. Cells were 
cultured for 7 days in differentiation media along with nanopowders. At the end of 7 days, 
cells were washed 1× with PBS to remove excess particles and fixed for 5 min with 4% 
paraformaldehyde. Cells were then washed 3× in PBS for 5 min each. Fixed cells were 
incubated for 1 h in 1% bovine serum albumin with 0.1% Triton-X. After blocking, cells 
were stained with Alexa Fluor 568 Phalloidin (1:400) (Molecular Probes) for 1 h at room 
temperature. After incubation, coverslips were rinsed in 1× PBS and washed for 3 × 5 min in 
1× PBS. Cell nuclei were then counterstained using NucBlue fixed cell ReadyProbe reagent 
(Molecular Probes) for 20 min. Images were obtained using a Zeiss LSM 710 confocal 
microscope (UIC core imaging facility).
2.5. In vivo implantation and histological analysis
Bone regeneration tests were conducted on 20 rats, Wister species. They were divided into 
two groups: one group, consisting of 5 animals, was the control group, whereas the other 
one, consisting of 15 animals, was the experimental group. The experimental group was 
further divided into three subgroups with five animals each. The rats in the first group had 
HAp powder implanted into the defect; the rats in the second group had HAp/Ch powder 
implanted into the defect; the rats in the third group had HAp/Ch-PLGA powder implanted 
into the defect.
The animals from the experimental group had defects introduced on the left side of the 
mandibular alveolar bone, in the region between the medial line and foramen mentale. The 
defect was created using a sterile steel borer, 1.6 mm in diameter and 1.8 mm in length 
depth. The animals had been prepared for this intervention by the application of diazepam 
(Bensendin, ICN Galenika, Belgrade, Serbia) and were subsequently anesthetized with 
ketamine hydrochloride USP (Ketalar, Rotexmedica Gmbh, Trittau, Germany). The animals 
in each group were sacrificed 4 weeks after the implantation. After the mentioned time 
interval, decalcified samples of the alveolar bone were taken, and after dehydration in a 
series of alcohol baths, paraffin blocks were made, out of which we took 10 μm wide 
fragments and counterstained according to the H&E method for histological analysis.
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The procedures involving experimental animals were done in accordance with the 
Guidelines for Work with Experimental Animals adopted by the Ethics Committee of the 
Faculty of Medicine, University of Niš, Serbia (No 01–2625/2013).
3. Results and discussion
Fig. 1 shows the XRD patterns of HAp, HAp/Ch and HAp/Ch-PLGA. The most intense 
peaks, observed at 31.8° (2 1 1), 32.2° (1 1 2), 32.9° (3 0 0), 25.9° (0 0 2) and 49.5° (2 1 3), 
originate from HAp. In accordance with the literature (International Center for Diffraction 
Data, JCPDS file No. 09–432) and our previous studies [18], the so obtained HAp 
diffractogram indicates a poorly crystalline, non-stoichiometric form. The diffractogram of 
HAp/Ch confirms the presence of both HAp and Ch. Namely, in addition to the 
characteristic peaks of HAp, the two reflections detected at 10.2° and 19.7° both originate 
from Ch [44]. The XRD pattern of HAp/Ch-PLGA displays no peaks originating from 
PLGA because this polymer is amorphous, which is in accordance with the XRD studies 
from our previous works [18–20].
The FE-SEM images of HAp, HAp/Ch and HAp/Ch-PLGA are shown in Fig. 2. The 
particles of HAp displayed a platelet-like morphology (Fig. 2a). However, after coating HAp 
with Ch (Fig. 2b), rounder particles were obtained compared to pure HAp. HAp/Ch-PLGA 
(Fig. 2c) particles had spherical morphologies too. The two-stage emulsification process, 
consisting of synthesis using a high-energy emulsifier and subsequent processing in the 
centrifugal field, had an important role in the promotion of spherical composite particle 
shapes.
For the qualitative confirmation of the content of the synthesized powders, HAp/Ch and 
HAp/Ch-PLGA were analyzed using FT-IR spectroscopy (Fig. 3). The IR spectrum of 
HAp/Ch (a) possessed exclusively the absorption bands characteristic for HAp and Ch. The 
double peak with maxima at 1088 and 1035 cm−1 is derived from the vibrations of the 
phosphate group ( ) of HAp. The broad band in the 3600–3000 cm−1 region is due to 
the stretching vibration of the hydroxyl group in water. The peaks at 1588 cm−1 and 1310 
cm−1 are amide II and amide III bands of chitosan. The sharp band at 2929 cm−1 is assigned 
to ν(CH) of the polysaccharide chitosan [45].
The analysis of the FT-IR spectra of HAp/Ch and HAp/Ch-PLGA reveals significant 
differences compared to the spectra of single-component materials [42]. Thus, the Ch-
derived band at 1655 cm−1 decreased in intensity, while the Ch-derived band at 1588 cm−1 
increased after the coating of HAp with Ch, indicating the possible interaction between the 
amide groups of Ch and OH− groups of HAp (Fig. 1a). Likewise, the stretching ν(C = O) 
vibration of the carbonyl group of pure PLGA exhibits a bathochromic shift from 1756 to 
1736 cm−1 (Fig. 1b), which might be due to the hydrogen bonding between C = O groups of 
PLGA and OH or NH2 groups of HAp or Ch, respectively.
Fig. 4 shows the simultaneously obtained results from TGA and on-line MS gas analysis. 
The TGA curve of synthesized HAp (Fig. 4a) has two noticeable regions. The first region, 
up to around 250 °C, is associated with the loss of water physisorbed on the surface of the 
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particles. In the region between 250 and 600 °C, a moderate loss of lattice water occurs, with 
a total decrease in mass of about 7% at 600 °C. These results are in line with the results of 
TG analyses of HAp reported by other authors in the temperature interval up to 600 °C [46].
The TGA curve of HAp/Ch (Fig. 4b) suggests that the detected changes in mass for the most 
part come from chitosan. The mild loss of mass up to 250 °C is associated with the loss of 
absorbed water. In the 250–600° C interval, there is a pronounced region of 250–300 °C 
with a significant drop in mass and the nearby 300–450 °C interval with a milder drop. The 
significant loss of mass in the temperature interval between 306 and 320 °C (Fig. 4b) is 
caused by the deacetylation of chitosan and is paralleled by the appearance of CH3COOH in 
the gas analysis. The release of H2O, CO, CO2 and CH3COOH in the 280–500 °C 
temperature interval has also been confirmed in FT-IR analyses by other authors [47]. 
Namely, the thermal degradation of chitosan polymeric chains in air, starting at ~250 °C, 
involves the pyrolysis of the polysaccharide structure that proceeds with the dissociation of 
the glycosidic bonds in the first step and is followed by the further decomposition yielding 
acetic and butyric acids, alongside a series of smaller fatty acids chains in the C3–C6 range 
[48,49].
As for PLGA, an abrupt loss of mass occurs in the temperature interval between 260 and 
400 °C, while a complete degradation is observed at temperatures higher than 400 °C (100% 
mass loss). The temperature of pyrolysis of PLGA is recorded as low as 255 °C, while its 
full degradation was noted to occur at the temperature of 400 °C during TGA carried out by 
other authors [50]. The TGA curve of HAp/Ch-PLGA, shown in Fig. 4c, is largely defined 
by the mass loss due to the thermal decomposition of Ch and PLGA. In the temperature 
interval between 260 °C and 400 °C, the loss of HAp/Ch-PLGA mass, beside Ch, comes 
from PLGA too and is confirmed by the maximum contents of CO2, H2O and CH3COOH in 
the corresponding MS gas analysis.
The synthesized HAp had a uniform distribution of particles with a diameter d50 = 70 nm 
(Fig. 5a). Following coating with the polymers, this value naturally increases. Thus, coating 
HAp with Ch produced particles of spherical morphology (Fig. 2b) and a diameter d50 = 
130 nm.
The obtained particle size distribution for HAp/Ch (Fig. 5b) suggests that there is a minor 
possibility of agglomerate formation since only 10% of the fraction of particles turn out to 
be larger than 260 nm (d90 = 260 nm). Coating the particles of HAp with Ch-PLGA 
polymer blend also leads to the formation of particles with a spherical morphology, for 
which d50 = 163 nm (Fig. 5c). HAp particles in all the composites retain the same diameter, 
and the subsequent increase in the diameter is solely the consequence of coating HAp with 
Ch or Ch-PLGA. Beside d90 = 820 nm, the tendency to form aggregates of HAp/Ch-PLGA 
particles can also be observed through the occurrence of visible adhesion between single 
particles.
The minimal inhibitory concentration (MIC) and the minimal microbicidal concentration 
(MMC) were different for all the three particle types (Table 1). Based on the results given in 
Table 1, a smaller amount of HAp/Ch particles had a significant effect on the viability of the 
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initial bacterial inoculum when compared to HAp and HAp/Ch-PLGA. Considering the MIC 
and MMC values, the antibacterial efficacy of samples increased in the following order: 
HAp < HAp/Ch-PLGA < HAp/Ch.
The nanoparticles of HAp exhibited a moderate antibacterial activity against both Gram-
positive and Gram-negative bacteria. The antimicrobial properties could be a consequence 
of the formation of various kinds of highly reactive oxygen species (OH−, H2O2, , ) 
on the surface of the nanoparticles, causing a lethal damage to the bacteria [51]. Beside a 
series of factors that define the antimicrobial properties of Ch, such as molecular weight 
(Mw) and the degree of deacetylation (DD), the positive surface charge density is perhaps 
the most crucial [52]. The main hypothesis of the antimicrobial activity of Ch is thus 
grounded in the ionic interaction between its positively charged amino groups and the 
negatively charged bacterial surface, which induces the permeability of the bacterial 
membrane, though without bacteriophages or Shiga toxins [53]. In our earlier research we 
determined the zeta potential values for the given particles at pH 6.5, corresponding to the 
average of the pH of the two broths utilized in this study (Mueller-Hinton – pH 7.3, 
Sabouraud dextrose – pH 5.6): HAp (−7.9 ± 0.8 mV), HAp/ Ch-PLGA (+3.0 ± 0.3 mV) and 
HAp/Ch (+18.3 ± 1.9 mV) [42]. Interestingly, as the zeta potential values increase from the 
negative to the positive, so does the antimicrobial potency of the three different types of 
particles – HAp, HAp/Ch-PLGA, HAp/Ch, respectively – increase too. Density of the most 
reactive functional groups in Ch (an amino/ acetamido group at position C-2, secondary and 
primary hydroxyl groups at positions C-3 and C-6, respectively) [54] is largest on the 
surface of HAp/Ch, and its highest antimicrobial potency is therefore to be expected.
The results of an immunohistochemistry analysis of the nanoparticle/cell interface 
demonstrated a relatively viable contact for all the three particles types (Fig. 6). Still, when 
compared to the perfect integration of pure HAp with the osteoblastic cell population in 
vitro, some level of reservation of the cells in relation to both forms of polymer-coated HAp 
is evident from the confocal optical micrographs presented in Fig.6. Zones adjacent to the 
particle surface and wholly vacated by cells are thus occasionally present in micrographs of 
cells incubated with HAp/Ch and HAp/Ch-PLGA. A possible reason may be the minor 
presence of glutaraldehyde and polyethylenepolypropylene glycol on the surfaces of 
HAp/Ch and HAp/Ch-PLGA, respectively, contributing to the mild repulsion experienced 
by the cells. Still, no adverse morphological indications were observed in the osteoblastic 
cells, suggesting that all the particle types could be potentially successfully applied for in 
vivo reconstruction of bone defects.
Histological images of osseous defects filled with HAp, HAp/Ch and HAp/Ch-PLGA 
powders four weeks after the reconstruction are shown in Fig 7. The area of the defect 
reconstructed with the material with the largest antimicrobial potency (HAp/Ch) exhibited 
the presence of inflammatory cells, lymphocytes, as well as of some amount of the 
implanted material (Fig 7c). “Race for the surface” is the term describing the competitive 
adherence of bacteria and bone cells onto the surface of freshly implanted biomaterials [55]. 
Its implication is that surfaces attracting the bone cells effectively attract the bacteria too. 
Conversely, this means that materials that are intensely antimicrobial in nature may be 
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expected to induce somewhat adverse effects upon implantation in the body, including a 
more intense inflammation.
Four weeks after the reconstruction with HAp/Ch-PLGA, the bone defect is seen filled with 
the newly grown bone tissue with Haversian canals present in it (Fig. 7d). High quality of 
the newly formed tissue is also reflected in the presence of cement lines. The appearance of 
the Haversian system with blood vessels after only four weeks following the reconstruction 
of the defect using HAp/Ch-PLGA is a strong indicator of accelerated osteogenesis. 
Blending Ch with PLGA earlier proved to be valid for the purpose of enhancing the 
properties of Ch, particularly its cellular uptake [56]. The number of osteoblast cells, as well 
as their proliferation, also happened to be the largest on the surface of the polymer blend Ch-
PLGA, when compared to pure HAp and HAp/Ch [57]. Our research concordantly 
demonstrates the viability of blending Ch with PLGA in these composite systems.
4. Conclusion
Utilizing the solvent/non-solvent precipitation method, along with freeze-dry processing, 
hydroxyapatite (HAp) nanoparticles were synthesized and subsequently coated with chitosan 
(HAp/Ch) and chitosanpoly-D,L-lactide-co-glycolide (HAp/Ch-PLGA) polymer blend. A 
thermogravimetric analysis coupled to on-line mass spectrometry confirmed the coating of 
the nanoparticulate HAp with Ch and with the Ch-PLGA blend. An immunohistochemistry 
analysis of the nanoparticle/cell interface demonstrated a relatively viable contact for all the 
particle types, though with a very minor level of reservation of osteoblastic cells in relation 
to both forms of polymer-coated HAp particles when compared to pure HAp. HAp/Ch 
exhibited the highest antimicrobial activity, but after the reconstruction of the bone defect it 
also caused visible inflammatory reactions in the newly formed tissue where the defect had 
lain. Blending chitosan coating with PLGA led to a decrease in the reactivity and the 
antimicrobial activity of the composite particles, but also to an increase in the quality of the 
newly formed bone tissue in the reconstructed defect area.
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Fig. 1. 
XRD of HAp, HAp/Ch and HAp/Ch-PLGA.
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Fig. 2. 
FE-SEM of HAp (a), HAp/Ch (b) and HAp/Ch-PLGA (c).
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Fig. 3. 
FT-IR spectra of HAp/Ch (a) and HAp/Ch-PLGA (b).
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Fig. 4. 
Thermal Analysis: TGA-on line MS (gas analysis) of HAp (a), HAp/Ch (b) and HAp/Ch-
PLGA (c).
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Fig. 5. 
Particle size distribution of HAp (a), HAp/Ch (b) and HAp/Ch-PLGA (c).
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Fig. 6. 
Confocal optical micrographs of fluorescently stained osteoblastic MC3T3-E1 cells 
following incubation with HAp (a), HAp/Ch (b) and HAp/Ch-PLGA (c). Cell nuclei are 
stained in blue and f-actin microfilaments are stained in red. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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Fig. 7. 
Histological analysis of the control and experimental groups of animals four weeks after the 
implantation: control (a), HAp (b), HAp/Ch (c) and HAp/Ch-PLGA (d). [1 — new bone 
tissue; 2 — blood vessel; 3 — filling defect with new tissue; 4 — implant material in 
substitution phase; 5 — cement lines; 6 — fibroblasts + fibrocytes; 7 — inflammatory cells 
— lymphocytes; 8 — implant material in substitution phase, surrounded by bone tissue and 
osteoblasts; 9 — osteogenesis; 10 — periosteum; 11 — Haversian canals with blood vessels 
and nerves].
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